Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An atlas of cells in the human tonsil.
Massoni-Badosa R, Aguilar-Fernández S, Nieto JC, Soler-Vila P, Elosua-Bayes M, Marchese D, Kulis M, Vilas-Zornoza A, Bühler MM, Rashmi S, Alsinet C, Caratù G, Moutinho C, Ruiz S, Lorden P, Lunazzi G, Colomer D, Frigola G, Blevins W, Romero-Rivero L, Jiménez-Martínez V, Vidal A, Mateos-Jaimez J, Maiques-Diaz A, Ovejero S, Moreaux J, Palomino S, Gomez-Cabrero D, Agirre X, Weniger MA, King HW, Garner LC, Marini F, Cervera-Paz FJ, Baptista PM, Vilaseca I, Rosales C, Ruiz-Gaspà S, Talks B, Sidhpura K, Pascual-Reguant A, Hauser AE, Haniffa M, Prosper F, Küppers R, Gut IG, Campo E, Martin-Subero JI, Heyn H. Massoni-Badosa R, et al. Among authors: moreaux j. Immunity. 2024 Feb 13;57(2):379-399.e18. doi: 10.1016/j.immuni.2024.01.006. Epub 2024 Jan 31. Immunity. 2024. PMID: 38301653 Free PMC article.
Transient loss of Polycomb components induces an epigenetic cancer fate.
Parreno V, Loubiere V, Schuettengruber B, Fritsch L, Rawal CC, Erokhin M, Győrffy B, Normanno D, Di Stefano M, Moreaux J, Butova NL, Chiolo I, Chetverina D, Martinez AM, Cavalli G. Parreno V, et al. Among authors: moreaux j. Nature. 2024 Apr 24. doi: 10.1038/s41586-024-07328-w. Online ahead of print. Nature. 2024. PMID: 38658752
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.
Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N, Requirand G, Cartron G, Vincent L, Herbaux C, Lutzmann M, Bret C, Pasero P, Moreaux J, Ovejero S. Bruyer A, et al. Among authors: moreaux j. Front Oncol. 2023 Dec 6;13:1271847. doi: 10.3389/fonc.2023.1271847. eCollection 2023. Front Oncol. 2023. PMID: 38125947 Free PMC article.
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Among authors: moreaux j. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, Herbaux C, Cavalli G, Bruyer A, De Boussac H, Moreaux J. Chemlal D, et al. Among authors: moreaux j. Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2. Leukemia. 2023. PMID: 37532787 Free PMC article. No abstract available.
252 results